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A commentary on
Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders
by Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D. Biol Psychiatry (2016) 80:179–89. 
doi: 10.1016/j.biopsych.2015.10.024
Kwako et al. recently proposed a neuroscience-based framework by which to classify substance use 
disorders (SUDs) (1). This is based on functional domains—incentive salience, negative emotionality, 
and executive function—derived from a cycle-of-addiction model. The authors provide a thoughtful 
literature synthesis as rationale for an associated Addictions Neuroclinical Assessment (ANA) aim-
ing to accelerate precision medicine research on relationships between genetic by environmental-
exposure interactions and phenotypic expression of these SUD domains. Precision medicine may 
be defined as “an emerging approach for disease treatment and prevention that takes into account 
individual variability in genes, environment, and lifestyle for each person” (2). The authors explain 
how ANA may guide multidimensional analyses informing how to customize SUD research and care 
to address cross-population and temporal variability in genetic and phenotypic expression of these 
domains tailored to different patient subgroups (1).
The introduction of a standardized neuroscience-based SUD assessment battery to advance 
precision medicine research is innovative and critical, and nicely complements similar efforts 
advanced by the U.S. National Institute of Mental Health’s Research Domain Criteria initiative (3–6). 
Utilizing standardized instruments for measuring core functional domains of SUD enables com-
parability across research studies, meta-analyses, and data mining to advance biomedical big-data 
research. However, improved standardized measurement on its own may not lead to translation of 
neuroscience-based research into better SUD care. For this to happen, research needs to incorporate 
two factors. First, studies are needed to validate how such domains may be used to tailor treatments 
to different levels of impairment and to test specificity and sensitivity of proposed ANA domains 
to SUD-related impairment. Study designs should also provide controls to account for the possible 
confounds in which participants who choose to frequently use alcohol or drugs might also have other 
co-occurring problems, either naturally or due to other lifestyle choices or circumstances. Target and 
biomarker validation—critical to expedite precision medicine research—necessitates such analyses.
Second, a concise assessment battery is essential to improve ease of use in deep-phenotyping 
efforts. Kwako et al.’s assessment battery is proposed to take a full 10 h to administer (1), which 
may place heavy burden on clinical researchers and most SUD patients—thus introducing a sample 
selection bias and compromising validity. A neuroscience-based nosology should be proposed with 
more precise functional domains, measured using a streamlined assessment battery of validated 
taBle 1 | Proposed measures: computer-based assessment with skip patterns to shorten length.
adult PromIS® domaina http://www.
healthmeasures.net/explore-measurement-
systems/promis/intro-to-promis/
list-of-adult-measures
Short forms up to a 
maximumd items (below), 
depending on research 
question
Computer adaptive tests (Cat)  
item bankse maximumd items 
(asked based on responses)
aSPIre model risk category mapping 
to adult PromIS® domain. For more 
information on aSPIre problem 
categories, see Ghitza (7, 8)f
Emotional distress—depression 8 30 (A) Anhedonia/reward-deficit state
Emotional distress—anxiety 8 29 (S) Stressful/anti-reward state
Pain interference 8 40 (S) 
Alcohol—negative expectanciesb 7 11 (S) 
Alcohol—negative consequencesb 7 31 (S)
Smoking—negative health expectanciesc 6 19 (S)
Smoking—coping expectanciesc 4 18 (S)
Smoking—negative psychosocial expectanciesc 6 20 (S)
Cognitive function 8 32 (P) Pathological lack of self-control to cut 
down substance use
Sleep-related impairment 8 16 (I) Insomnia associated with substance use/
impairment; (R) Restlessness
Alcohol—positive expectanciesb 7 9 (E) Excessive preoccupation with seeking drug 
reinforcers
Alcohol—positive consequencesb 7 20 (E)
Smoking—nicotine dependencec 8 27 (E)
Smoking—emotional/sensory expectanciesc 6 17 (E)
Separate from PROMIS® Domains: PhenX 
Core Tier-1 Measures of Substance Abuse and 
Addiction Collection, as well as Core Tier-2 
Measures whenever possible and appropriated
Not applicable Not applicable Applicable to assessing substance 
use, demographics, and other clinical 
characteristics
aFor more information, see Ref. (9).
bApplicable to all alcohol drinkers, daily alcohol drinkers, or non-daily alcohol drinkers.
cApplicable to all nicotine smokers, daily nicotine smokers, or non-daily nicotine smokers.
dFor more information: Notice Announcing Data Harmonization for Substance Abuse and Addiction via the PhenX Toolkit: Notice Number: NOT-DA-12-008 [Internet]. Bethesda, 
MD: National Institutes of Health (US) (2016). Available from: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-12-008.html, https://www.phenxtoolkit.org/index.
php?pageLink=browse.core.tier1.
ePer the PROMIS website, regarding time to administer “each CAT takes 1–2 min. If you take three CATs, it will take 3–6 min to answer all the questions and get your report.” 
Examples of the PROMIS CATs may be found at https://www.assessmentcenter.net/ac1/Assessments/CATDemo.
fMapping ASPIRE problem categories to the ANA domains.
ASPIRE problem categories A, S, and I map on to the ANA’s negative emotionality domain.
P and R map on to ANA’s executive function.
E maps on to ANA’s incentive salience.
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instruments. To shorten the battery and enhance its feasible 
administration across clinical and research situations, modifi-
able assessments are necessary, tailored to risk categories. These 
could be based upon a shared decision-making approach where 
research participants are queried on functional domains most 
impeding their overall well-being. Such modifiable assessments 
would shorten the ANA, by incorporating only those phenotypic 
measurements deemed to be most relevant to functioning of 
particular participants.
More rigorous research is needed to systematically evaluate 
a patient-centered, neuroscience-based framework for treating 
SUDs—testing a shared decision-making, precision medicine 
approach tailored to salient risk categories of each participant. 
Pre-dating the ANA, in 2014, I developed an approach, termed 
the ASPIRE model (7, 8), that uses as its foundational prin-
ciple shared decision making between patients and providers 
to tailor personalized medical care and precision medicine 
research to six neuroscience-based risk categories in which 
individual patients report as most distressing to their daily lives. 
The ASPIRE-framework risk categories—proposed based on over 
30  years of neuroscience research and representing common 
pathophysiological factors related to etiology and perpetuation 
of substance use-related problems—include the following. (A) 
Anhedonia/reward-deficit state; (S) Stressful/anti-reward state; 
(P) Pathological lack of self-control to cut down substance 
use despite undesired consequences; (I) Insomnia associated 
with substance use and worsening functional impairment; (R) 
Restlessness associated with the above; (E) Excessive preoc-
cupation with seeking drug reinforcers, compared with natural 
reinforcers, following transition from volitional to compulsive 
drug use, particularly associated with craving on exposure to a 
drug-associated environment (7, 8). The precise meaning of these 
empirically derived constructs is subjected to change in the basis 
of ongoing research.
Table  1 presents a proposal for a more succinct assessment 
battery of validated standardized instruments that map onto 
these risk categories. This could serve as a model for phenotyp-
ing purposes and to advance biomedical big-data science using 
standardized data collection, which permits pooling data for 
SUD precision medicine research. Assessment battery of Table 1 
contains relevant PROMIS® (Patient-Reported Outcomes 
Measurement Information System) measures (9). These have been 
developed and validated with U.S. National Institutes of Health 
funding, utilizing state-of-the-science item response theory and 
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other statistical methods to be psychometrically sound. These 
measures are intended to comprise a brief assessment battery, 
which would be administered using computer adaptive tests 
containing skip patterns where they would only be presented to 
participants if they assess risk categories participants report as 
being most pertinent to their functional impairments. Otherwise, 
these questions would be omitted, which would substantially 
shorten length of administration and minimize burden on 
researchers and participants alike, thereby enhancing feasibility 
and ecological validity to most research and clinical situations. 
This proposed question set also contains Core Tier-1 measures 
of Substance Abuse and Addiction project of the phenotypes and 
exposures (PhenX) Toolkit, and Core Tier-2 measures whenever 
possible and appropriate. The U.S. National Institute on Drug 
Abuse (NIDA) strongly encourages all NIDA supported human 
subjects researchers to use standardized measures to facilitate 
measure commonality and data comparability (10). Notably, all 
suggested measures are non-proprietary and open-source, which 
could broaden use by minimizing cost. Use of data standards a 
means to promote cross-study comparisons and combined data 
analyses needed to validate and extend human subjects research 
results.
To conclude, Kwako et al. recently proposed an ANA, which 
includes a broad myriad of neuroscience-based functional 
domains associated with a SUD nosology together with a long 
battery. To maximize applicability among various clinical research 
situations and for collection as part of a patient registry or via 
electronic health record systems, it would be vital to tailor assess-
ments and present only those pertaining to SUD risk categories or 
functional domains reported as being most salient to the research 
participant. Therefore, for deep-phenotyping purposes applicable 
to precision medicine research, a leaner, customizable assessment 
battery omitting less relevant measures, would be an important 
tool to advance research in this area.
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